{"url_path":"/sec/srts/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1494891/0001753926-26-000845-index.html","accession_number":"0001753926-26-000845","cik":"0001494891","ticker":"SRTS","issuer_name":"Sensus Healthcare, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1494891/0001753926-26-000845-index.html","primary_entity_key":"0001494891","primary_entity_name":"Sensus Healthcare, Inc."},"word_count":1479,"has_tables":true,"body_markdown":"false\n--12-31\n2026\nQ1\n0001494891\n\n0\n\nP10Y\n\n0001494891\n\n2026-01-01\n2026-03-31\n\n0001494891\n\n2026-05-06\n\n0001494891\n\n2026-03-31\n\n0001494891\n\n2025-12-31\n\n0001494891\n\n2025-01-01\n2025-03-31\n\n0001494891\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001494891\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001494891\n\nus-gaap:TreasuryStockCommonMember\n\n2024-12-31\n\n0001494891\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001494891\n\n2024-12-31\n\n0001494891\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001494891\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001494891\n\nus-gaap:TreasuryStockCommonMember\n\n2025-12-31\n\n0001494891\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001494891\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001494891\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001494891\n\nus-gaap:TreasuryStockCommonMember\n\n2025-01-01\n2025-03-31\n\n0001494891\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001494891\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001494891\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001494891\n\nus-gaap:TreasuryStockCommonMember\n\n2026-01-01\n2026-03-31\n\n0001494891\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001494891\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001494891\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001494891\n\nus-gaap:TreasuryStockCommonMember\n\n2025-03-31\n\n0001494891\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001494891\n\n2025-03-31\n\n0001494891\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001494891\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001494891\n\nus-gaap:TreasuryStockCommonMember\n\n2026-03-31\n\n0001494891\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001494891\n\nus-gaap:ProductMember\n\n2026-01-01\n2026-03-31\n\n0001494891\n\nus-gaap:ProductMember\n\n2025-01-01\n2025-03-31\n\n0001494891\n\nsrts:ProductRevenueMember\n\n2026-01-01\n2026-03-31\n\n0001494891\n\nsrts:ProductRevenueMember\n\n2025-01-01\n2025-03-31\n\n0001494891\n\nus-gaap:ServiceMember\n\n2026-01-01\n2026-03-31\n\n0001494891\n\nus-gaap:ServiceMember\n\n2025-01-01\n2025-03-31\n\n0001494891\n\nsrts:ServiceRevenueMember\n\n2026-01-01\n2026-03-31\n\n0001494891\n\nsrts:ServiceRevenueMember\n\n2025-01-01\n2025-03-31\n\n0001494891\n\nus-gaap:ProductMember\n\n2025-12-31\n\n0001494891\n\nus-gaap:ServiceMember\n\n2025-12-31\n\n0001494891\n\nus-gaap:ProductMember\n\n2026-03-31\n\n0001494891\n\nus-gaap:ServiceMember\n\n2026-03-31\n\n0001494891\n\nsrts:ServiceRevenueMember\n\n2026-03-31\n\n0001494891\n\nsrts:CustomerMember\nus-gaap:CustomerConcentrationRiskMember\nus-gaap:SalesRevenueNetMember\n\n2026-01-01\n2026-03-31\n\n0001494891\n\nsrts:CustomerOneMember\nus-gaap:CustomerConcentrationRiskMember\nus-gaap:SalesRevenueNetMember\n\n2026-01-01\n2026-03-31\n\n0001494891\n\nsrts:CustomerMember\nus-gaap:CustomerConcentrationRiskMember\nus-gaap:SalesRevenueNetMember\n\n2025-01-01\n2025-03-31\n\n0001494891\n\nsrts:CustomerMember\nus-gaap:CustomerConcentrationRiskMember\nus-gaap:AccountsReceivableMember\n\n2026-03-31\n\n0001494891\n\nsrts:CustomerOneMember\nus-gaap:CustomerConcentrationRiskMember\nus-gaap:AccountsReceivableMember\n\n2026-03-31\n\n0001494891\n\nsrts:CustomerMember\nus-gaap:CustomerConcentrationRiskMember\nus-gaap:AccountsReceivableMember\n\n2025-12-31\n\n0001494891\n\ncountry:US\n\n2026-01-01\n2026-03-31\n\n0001494891\n\ncountry:US\n\n2025-01-01\n2025-03-31\n\n0001494891\n\ncountry:CN\n\n2026-01-01\n2026-03-31\n\n0001494891\n\ncountry:CN\n\n2025-01-01\n2025-03-31\n\n0001494891\n\nsrts:OtherMember\n\n2026-01-01\n2026-03-31\n\n0001494891\n\nsrts:OtherMember\n\n2025-01-01\n2025-03-31\n\n0001494891\n\nsrts:EarningsPerShareMember\n\n2026-01-01\n2026-03-31\n\n0001494891\n\nsrts:EarningsPerShareMember\n\n2025-01-01\n2025-03-31\n\n0001494891\n\nsrts:RestrictedStockawardsMember\n\n2026-01-01\n2026-03-31\n\n0001494891\n\nsrts:RestrictedStockawardsMember\n\n2025-01-01\n2025-03-31\n\n0001494891\n\nsrts:StockOptionsMember\n\n2026-01-01\n2026-03-31\n\n0001494891\n\nsrts:StockOptionsMember\n\n2025-01-01\n2025-03-31\n\n0001494891\n\nus-gaap:EquipmentMember\n\n2026-03-31\n\n0001494891\n\nus-gaap:EquipmentMember\n\n2025-12-31\n\n0001494891\n\nus-gaap:EquipmentMember\nsrt:MinimumMember\n\n2026-03-31\n\n0001494891\n\nus-gaap:EquipmentMember\nsrt:MaximumMember\n\n2026-03-31\n\n0001494891\n\nsrts:FDAProgramEquipmentMember\n\n2026-03-31\n\n0001494891\n\nsrts:FDAProgramEquipmentMember\n\n2025-12-31\n\n0001494891\n\nsrts:TradeshowAndDemoEquipmentMember\n\n2026-03-31\n\n0001494891\n\nsrts:TradeshowAndDemoEquipmentMember\n\n2025-12-31\n\n0001494891\n\nus-gaap:ComputerEquipmentMember\n\n2026-03-31\n\n0001494891\n\nus-gaap:ComputerEquipmentMember\n\n2025-12-31\n\n0001494891\n\nus-gaap:ResearchAndDevelopmentArrangementMember\n\n2026-03-31\n\n0001494891\n\nus-gaap:ResearchAndDevelopmentArrangementMember\n\n2025-12-31\n\n0001494891\n\nsrts:ComericaBankMember\n\n2023-09-30\n\n0001494891\n\nsrt:MaximumMember\n\n2024-10-31\n\n0001494891\n\nus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember\n\n2026-01-01\n2026-03-31\n\n0001494891\n\nus-gaap:LineOfCreditMember\n\n2026-01-01\n2026-03-31\n\n0001494891\n\nsrts:OperatingLeaseAgreementsMember\n\n2026-01-01\n2026-03-31\n\n0001494891\n\nsrts:OperatingLeaseAgreementsMember\n\n2025-01-01\n2025-03-31\n\n0001494891\n\nsrts:EquityIncentivesPlansMember\n\n2026-03-31\n\n0001494891\n\nsrts:EquityIncentivesPlan1Member\n\n2026-03-31\n\n0001494891\n\nsrts:EquityIncentivesPlan2Member\n\n2026-03-31\n\n0001494891\n\nsrts:EquityIncentivePlanMember\nus-gaap:RestrictedStockMember\n\n2022-12-19\n\n0001494891\n\n2022-12-18\n2022-12-19\n\n0001494891\n\nus-gaap:RestrictedStockMember\nsrts:EquityIncentivePlanMember\n\n2024-01-10\n2024-01-11\n\n0001494891\n\nsrts:EquityIncentivePlanMember\nus-gaap:CommonStockMember\n\n2024-01-10\n2024-01-11\n\n0001494891\n\nsrts:EquityIncentivePlanMember\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-01-31\n\n0001494891\n\nsrts:EquityIncentivePlanMember\n\n2024-01-10\n2024-01-11\n\n0001494891\n\nsrts:EquityIncentivePlanMember\nsrts:EquityIncentivePlanMember\n\n2024-12-16\n2024-12-17\n\n0001494891\n\nsrts:EquityIncentivePlanMember\nus-gaap:CommonStockMember\n\n2024-12-16\n2024-12-17\n\n0001494891\n\nsrts:EquityIncentivePlanMember\nus-gaap:CommonStockMember\n\n2024-12-17\n\n0001494891\n\n2024-12-16\n2024-12-17\n\n0001494891\n\nsrts:EquityIncentivePlanMember\n\n2024-12-16\n2024-12-17\n\n0001494891\n\nsrts:EquityIncentivePlanMember\nsrts:EquityIncentivePlanMember\n\n2025-12-11\n2025-12-12\n\n0001494891\n\nsrts:EquityIncentivePlanMember\nus-gaap:CommonStockMember\n\n2025-12-11\n2025-12-12\n\n0001494891\n\nsrts:EquityIncentivePlanMember\n\n2025-12-11\n2025-12-12\n\n0001494891\n\nus-gaap:RestrictedStockMember\n\n2026-01-01\n2026-03-31\n\n0001494891\n\nus-gaap:RestrictedStockMember\n\n2025-01-01\n2025-03-31\n\n0001494891\n\nus-gaap:RestrictedStockMember\n\n2025-12-31\n\n0001494891\n\nus-gaap:RestrictedStockMember\n\n2026-03-31\n\n0001494891\n\nus-gaap:StockOptionMember\n\n2025-12-31\n\n0001494891\n\nus-gaap:StockOptionMember\n\n2025-01-01\n2025-12-31\n\n0001494891\n\nus-gaap:StockOptionMember\n\n2026-01-01\n2026-03-31\n\n0001494891\n\nus-gaap:StockOptionMember\n\n2026-03-31\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION** \n\n**WASHINGTON,\nD.C. 20549**\n\n** **\n\n**FORM\n10-Q**\n\n \n\n☒\n**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE**\n\n**ACT OF 1934**\n\n** **\n\n**For\nthe quarterly period ended March 31, 2026**\n\n** **\n\n**OR**\n\n** **\n\n☐\n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE**\n\n**ACT OF 1934**\n\n** **\n\n**FOR\nTHE TRANSITION PERIOD FROM ____________ TO ____________**\n\n** **\n\n**Commission\nFile Number: 001-37714**\n\n** **\n\n**Sensus\nHealthcare, Inc.** \n\n(Exact\nname of registrant as specified in its charter)\n\n \n\n**Delaware**\n \n**27-1647271**\n\n(State or other jurisdiction\nof\n\nincorporation or organization)\n \n(I.R.S. Employer\n\nIdentification No.)\n\n \n\n**851\nBroken Sound Pkwy., NW #215, Boca Raton, FL**\n \n**33487**\n\n(Address of principal\nexecutive office)\n \n(Zip Code)\n\n \n\n**(561)\n922-5808 **\n\n(Registrant’s\ntelephone number, including area code)\n\n \n\n**Securities\nregistered pursuant to Section 12(b) of the Act:**\n\n** **\n\n**Title\nof each class**\n \n**Trading\nsymbol(s)**\n \n**Name\nof each exchange on which registered**\n\nCommon Stock, par\nvalue $0.01 per share\n \nSRTS\n \nThe NASDAQ Stock\nMarket, LLC\n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),\nand (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant\nto Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that\nthe registrant was required to submit such files). Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting\ncompany, or an “emerging growth company.” See the definitions of “large accelerated filer,” “accelerated\nfiler,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange\nAct.\n\n \n\nLarge accelerated filer ☐\n \nAccelerated filer ☐\n \nNon-accelerated filer ☒\n \nSmaller reporting company\n☒\n\n \n \n \n \n \n \nEmerging growth company ☐\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for\ncomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n \n\nAs\nof May 6, 2026 , there were 16,462,059 shares of the registrant’s common stock outstanding.\n\n1\n\n \n\n**SENSUS\nHEALTHCARE, INC. **\n\n**QUARTERLY\nREPORT ON FORM 10-Q** \n\n**TABLE\nOF CONTENTS**\n\n** **\n\n \n \n**Page**\n\n[PART I – Financial Information](#a001_v1)\n \n\n \n \n \n\n[Item 1.](#a002_v1)\n[Condensed Consolidated Financial Statements (unaudited)](#a002_v1)\n4\n\n \n \n \n\n \n[Condensed Consolidated Balance Sheets (unaudited)](#a003_v1)\n4\n\n \n \n \n\n \n[Condensed Consolidated Statements of Loss (unaudited)](#a004_v1)\n5\n\n \n \n \n\n \n[Condensed Consolidated Statements of Stockholders’ Equity (unaudited)](#a005_v1)\n6\n\n \n \n \n\n \n[Condensed Consolidated Statements of Cash Flows (unaudited)](#a006_v1)\n7\n\n \n \n \n\n \n[Notes to the Condensed Consolidated Financial Statements (unaudited)](#a007_v1)\n8\n\n \n \n \n\n[Item 2.](#a008_v1)\n[Management’s Discussion\nand Analysis of Financial Condition and Results of Operations](#a008_v1)\n22\n\n \n \n \n\n[Item 3.](#a009_v1)\n[Quantitative and Qualitative Disclosures about Market Risk](#a009_v1)\n27\n\n \n \n \n\n[Item 4.](#a010_v1)\n[Controls and Procedures](#a010_v1)\n27\n\n \n \n \n\n[PART II – Other Information](#a011_v1)\n \n\n \n \n \n\n[Item 1.](#a012_v1)\n[Legal Proceedings](#a012_v1)\n27\n\n \n \n \n\n[Item 1A.](#a013_v1)\n[Risk Factors](#a013_v1)\n27\n\n \n \n \n\n[Item 2.](#a014_v1)\n[Unregistered Sales of Equity\nSecurities and Use of Proceeds](#a014_v1)\n27\n\n \n \n \n\n[Item 3.](#a015)\n[Defaults Upon Senior Securities](#a015)\n28\n\n \n \n \n\n[Item 4.](#a016)\n[Mine Safety Disclosure](#a016)\n28\n\n \n \n \n\n[Item 5.](#a017_v1)\n[Other Information](#a017_v1)\n28\n\n \n \n \n\n[Item 6.](#a018_v1)\n[Exhibits](#a018_v1)\n29\n\n \n \n \n\n \n[Signatures](#a019_v1)\n30\n\n2\n\n \n\n**INTRODUCTORY\nNOTE**\n\n**Forward-Looking\nStatements**\n\n  \n\nThis\nreport includes statements that are, or may be deemed, “forward-looking statements.” In some cases, these statements\ncan be identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,”\n“expects,” “plans,” “intends,” “may,” “could,” “might,”\n“will,” “should,” “approximately,” or “potential,” or negative or other variations\nof those terms or comparable terminology, although not all forward-looking statements contain these words.\n\n \n\nForward-looking\nstatements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus Healthcare,\nInc., our industry, and/or general economic or other conditions that may or may not occur in the future or may occur on longer\nor shorter timelines or to a greater or lesser degree than anticipated. In addition, even if future events, developments and circumstances\nare consistent with the forward-looking statements contained in this report, they may not be predictive of results or developments\nin future periods. Although we believe that we have a reasonable basis for each forward-looking statement contained in this report,\nforward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition\nand liquidity, and the development of the industry in which we operate, may differ materially from the forward looking statements\ncontained in this report as a result of the following factors, among others: the level and availability of government and/or third\nparty payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers to purchase\nour products if the level of reimbursement declines; concentration of our customers in the U.S. and China, including the concentration\nof sales to one particular customer in the U.S.; the development by others of new products, treatments, or technologies that render\nour technology partially or wholly obsolete; the regulatory requirements applicable to us and our competitors; our ability to\nefficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign countries,\nincluding ongoing geopolitical tensions between the U.S. and China; legislation, regulation, or other governmental action that\naffects our products, taxes, international trade regulation (including the possibility of tariffs and fluctuations in tariffs\non equipment we export or materials we import), or other aspects of our business; the performance of the Company’s information\ntechnology systems and its ability to maintain data security; the possibility that inflationary pressures continue to impact our\nsales; our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability\nto avoid infringing or otherwise violating the intellectual property rights of third parties; and other risks described from time\nto time in our filings with the Securities and Exchange Commission.\n\n \n\nTo\ndate, geopolitical uncertainties other than those relating to China have not had any significant impact on our business, but we\ncontinue to monitor developments and will address them in future disclosures, if applicable.\n\nAny\nforward-looking statements that we make in this report speak only as of the date of such statement, and we undertake no obligation\nto update such statements to reflect events or circumstances after the date this report is filed, except as may be required by\napplicable law.\n\n3\n\n \n\n**PART\nI. FINANCIAL INFORMATION**"}